These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 1726206)

  • 61. Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin.
    Portier H; Chavanet P; Waldner-Combernoux A; Kisterman JP; Grey PC; Ichou F; Safran C
    Scand J Infect Dis; 1994; 26(1):59-66. PubMed ID: 8191242
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Treatment of acute maxillary sinusitis in adults. Comparison of cefpodoxime-proxetil and amoxicillin-clavulanic acid].
    Polonovski JM; El Mellah M
    Presse Med; 2006 Jan; 35(1 Pt 1):33-8. PubMed ID: 16462661
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Amoxicillin/clavulanic acid vs cefetamet pivoxil in the treatment of acute exacerbation of chronic bronchitis (AECB) in adults.
    Behler PG; Böge K; Böhning W; Gams W; Gartner-Toth M; Wettengel R
    J Chemother; 1995 May; 7 Suppl 1():16-20. PubMed ID: 8618108
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical efficacy of cefpodoxime in respiratory tract infection.
    Cohen R
    J Antimicrob Chemother; 2002 Jul; 50 Suppl():23-7. PubMed ID: 12077157
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical trials of cefpodoxime proxetil suspension in paediatrics.
    Fujii R
    Drugs; 1991; 42 Suppl 3():57-60. PubMed ID: 1726209
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cefpodoxime proxetil for infective exacerbations of chronic obstructive airway disease.
    Alderman CP
    Ann Pharmacother; 1996 Feb; 30(2):196. PubMed ID: 8835062
    [No Abstract]   [Full Text] [Related]  

  • 68. Microbiology of bacterial respiratory infections.
    Cappelletty D
    Pediatr Infect Dis J; 1998 Aug; 17(8 Suppl):S55-61. PubMed ID: 9727651
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
    Kayser FH
    Infection; 1994; 22(5):370-5. PubMed ID: 7843823
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antibiotic-sensitivity of Moraxella catarrhalis isolated from clinical materials in 1997-1998.
    Mikucka A; Janicka G; Krawiecka D; Kochanowska J
    Med Sci Monit; 2000; 6(2):300-4. PubMed ID: 11208326
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.
    Verghese A; Roberson D; Kalbfleisch JH; Sarubbi F
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1041-4. PubMed ID: 2118322
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Clinical studies on cefpodoxime proxetil dry syrup in the field of pediatrics].
    Haruta T; Kuroki S; Hashimoto N; Suzuki N; Okura K; Kobayashi Y
    Jpn J Antibiot; 1989 Jul; 42(7):1621-8. PubMed ID: 2562790
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice].
    Brambilla C; Benhamou D; Guérin JC; Kelkel E; Muir JF; Prud'homme A; Taytard A; Fauche A
    Pathol Biol (Paris); 1995 Nov; 43(9):815-24. PubMed ID: 8746104
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Clinical evaluation of meropenem in the pediatric field].
    Mikuni K; Matsuda H; Watanabe N
    Jpn J Antibiot; 1992 Jun; 45(6):738-43. PubMed ID: 1507405
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A review of the pharmacokinetics of cefpodoxime proxetil.
    Borin MT
    Drugs; 1991; 42 Suppl 3():13-21. PubMed ID: 1726203
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Perry CM; Brogden RN
    Drugs; 1996 Jul; 52(1):125-58. PubMed ID: 8799689
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
    Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients.
    Backhouse C; Wade A; Williamson P; Tremblay D; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():29-34. PubMed ID: 2292527
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Clinical and bacteriological effects of cefetamet pivoxil against community-acquired respiratory tract infections. Part II].
    Shimada J; Ishihara R; Suzuki Y; Ishii Y; Nakazawa A; Deguchi K
    Jpn J Antibiot; 1997 Sep; 50(9):756-67. PubMed ID: 9394236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.